[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasma-cell-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasma-cell-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,72,84,106,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053329","pre-malignant-states-to-hematologic-malignancies-in-firefighters-100053329",false,"NCT06870760","Pre-malignant States to Hematologic Malignancies in Firefighters","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information.\n2. Age ≥ 40-49 years at the time of consent (self-reported)\n3. Ability of the participant to understand and comply with study procedures for the entire length of the study\n4. Currently employed by Charlotte Fire Department (CFD) with at least 5 years on-the -job experience (self-reported)\n\nExclusion Criteria:\n\nAnyone with a current diagnosis of a hematologic malignancy will be excluded.",true,"ALL","40 Years","49 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.",[25,26,27,28,29,30],"Clonal Hematopoiesis of Indeterminate Potential","Monoclonal Gammopathy","Non Hodgkin Lymphoma","Leukemia","Multiple Myeloma","Plasma Cell Disorder",[32,33,34],"Firefighters","CHIP","MGUS","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-06-23",{"date":43,"type":21},"2027-04",{"name":45,"class":46},"Wake Forest University Health Sciences","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100540181","phase-1-high-dose-ascorbic-acid-hdaa-in-patients-with-plasma-cell-disorders-100540181","NCT06313502","High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders","Inclusion Criteria:\n\n1. Subject has provided informed consent.\n2. Participants who are 18 years of age or older\n3. Subjects who have been previously treated with 3 or more lines of therapy (i.e., proteasome inhibitors, immunomodulatory agents such as lenalidomide, and monoclonal antibodies such as daratumumab) and have progressed within past 6 months.\n4. Subjects who have at least 1x106\u002Fkg CD34 stem cells in storage\n5. Subjects must have measurable disease (as determined by the UAMS clinical lab), including at least one of the criteria below. Tests performed as SOC within 30 days of the first dose may be utilized:\n\n   * M-protein quantities ≥ 0.5 gm\u002Fdl by SPEP\n   * ≥ 200 mg\u002F24-hour urine collection by UPEP\n   * serum-free light chain levels \\> 100 mg\u002FL (milligrams\u002Fliter involved light chain) and an abnormal kappa\u002Flambda (κ\u002Fλ) ratio in subjects without detectable serum or urine m-protein\n   * a serum IgA level ≥ 500 mg\u002FdL for subjects with immunoglobulin class A (IgA) myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement\n   * Non-secretory subjects are eligible provided the subject has \\> 20% BM plasmacytosis, OR multiple plasmacytomas or lesions (≥3) on MRI at the time of diagnosis or study enrollment, OR the presence of lesions (≥ 3) on PET\u002FComputerized Tomography (CT) scan.\n6. Adequate organ function reflects the following:\n\n   * Absolute neutrophil count (ANC) ≥ 0.5 x 109\u002FL without growth factor support for 7 days (14 days if pegfilgastrim).\n   * Platelets ≥ 25 x 109\u002FL without transfusion for 7 days. However, subject can be enrolled if the ANC and platelets are low due to disease\n   * Potassium within normal limits or correctable with supplements\n   * Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN)\n   * Serum bilirubin ≤ 1.5 x ULN\n   * Estimated serum creatinine clearance of ≥ 45 mL\u002Fmin using the Cockcroft-Gault equation or directly calculated from the 24-hour urine collection method\n   * International normalized ratio (INR) \\\u003C 1.5 x ULN and partial thromboplastin time \\\u003C 1.5 x ULN\n   * Ejection fraction by ECHO or MUGA of ≥ 40% performed\n   * Subjects must have adequate pulmonary function studies (PFTs) \\> 50% of predicted on mechanical aspects (forced expiratory volume, forced vital capacity) and \\> 50% of predicted (adjusted for hemoglobin) on diffusion capacity. If the participant is unable to complete PFTs due to disease-related pain or other circumstances that make it difficult to reliably perform PFTs, documentation of pulmonary function adequate for transplant will occur via a CT scan without evidence of major pulmonary disease and arterial blood gas results.\n7. Subjects must have a performance status of 0-2 based on ECOG performance criteria. Subjects with poor performance status (3-4) based solely on bone pain will be eligible if there is documentation to verify this.\n8. Negative serum or urine pregnancy test (sensitivity of at least 25 mIU\u002FmL) at screening.\n\nExclusion Criteria:\n\n1. Prior allogeneic transplant.\n2. Known hypersensitivity or allergy to ascorbic acid or melphalan, or any Grade 3 or higher AE as a result of test dose given during screening (15 gm).\n3. Subjects must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention. Participants may have a history of prior malignancy without any chemotherapy within 365 days of study entry AND life expectancy exceeding 5 years at the time of study entry.\n4. Subjects must not have life-threatening comorbidities as assessed by the investigator.\n5. History or evidence of MM associated with immunodeficiency states (e.g., hereditary immune deficiency, human immunodeficiency virus (HIV), organ transplant, or leukemia).\n6. Known HIV disease (requires negative test for clinically suspected HIV infection).\n7. Evidence of CNS myeloma.\n8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recent (within 6 months) myocardial infarction, uncontrolled or symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension on appropriate therapy or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n9. Concurrent use of coumadin (warfarin).\n10. Glucose-6-phosphate dehydrogenase deficiency as defined by blood test at screening visit.\n11. Pre-existing renal insufficiency or renal failure, a known history of renal stones, or who are undergoing dialysis.\n12. Diabetic subjects who are insulin dependent.\n13. Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.","18 Years","100 Years",{"count":57,"type":21},18,"INTERVENTIONAL",[60],"PHASE1","The purpose of this research is to evaluate whether HDAA in combination with a single dose of 100 mg\u002Fm2 IV melphalan followed by autologous stem cell transplantation (ASCT) is safe and effective for subjects with relapsed refractory multiple myeloma. The proposed melphalan dose is 50% of the current standard myeloablative dose (200 mg\u002Fm2). Based on our preclinical data, the investigator hypothesize that the combination of reduced dose melphalan with IV HDAA will have high efficacy and tolerability\n\nPrimary Objective To determine tumor response using International Myeloma Working Group (IMWG) criteria (see Appendix B).\n\nSecondary Objectives\n\nObjectives:\n\n1. Determine the safety and tolerability of HDAA in combination with reduced dose melphalan conditioning and autologous stem cell transplantation (ASCT) in relapsed refractory multiple myeloma subjects.\n2. Determine the rate of Minimal Residual Disease (MRD) negativity at time point of response assessment using 8 color flow cytometry on BM sample. Functional imaging, such as positron emission tomography (PET) scan and magnetic resonance imaging (MRI), will also be performed to assess the disease status.\n3. Categorize and quantify adverse events compared to historical control.\n4. Determine quality of life parameters using standardized health-related quality of life measures\n5. Determine oxidative stress parameters in plasma during treatment.",[30],"2026-06-02",{"date":65,"type":39},"2026-06-04",{"date":67,"type":39},"2024-07-19",{"date":69,"type":21},"2028-04",{"name":71,"class":46},"University of Arkansas",{"id":73,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":75,"keywords":76,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":47},"100583010",{"count":20,"type":21},[25,26,27,28,29,30],[32,33,34],"2026-04-13",{"date":79,"type":39},"2026-04-16",{"date":81,"type":21},"2026-06",{"date":43,"type":21},{"name":45,"class":46},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":58,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100598747","phase-1-subcutaneous-daratumumab-administration-in-the-thigh-vs-abdomen-in-plasma-cell-disorders-100598747","NCT07075510","Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders","A Phase I\u002FII Study of Subcutaneous Daratumumab Administration in the Anterior Upper Thigh Vs Abdomen in Patients With Plasma Cell Disorders","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of MM (newly diagnosed or relapsed) or AL amyloid with planned therapy with daratumumab-based regimen. and has not received daratumumab previously or has received daratumumab \\> 6 months prior to planned Cycle 1 Day 1 alone or in combination with other regimens per investigator discretion.\n2. Provide signed written informed consent\n3. 18 years or older (at the time consent is obtained)\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n5. Participants with a history of autologous stem cell transplant or prior CAR-T cell therapy can enroll on the study provided that:\n\n   1. Therapy was \\>100 days prior to study enrollment\n   2. No active infection(s)\n6. Adequate organ system function\n7. Female participants: Contraceptive use for those participating in clinical studies (men or women) should be consistent with local regulations: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n   1. Is not a woman of childbearing potential (WOCBP) OR\n   2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), preferably with low user dependency, during the intervention period and for at least 12 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.\n\n      * A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.\n      * We will review the medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a new undetected pregnancy.\n\n   Non childbearing potential is defined as follows (by other than medical reasons):\n   * ≥45 years of age and has not had menses for \\>1 year\n   * Patients who have been amenorrhoeic for \\\u003C2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range\n   * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.\n8. Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n   Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:\n\n   a. Refrain from donating sperm PLUS either:\n   * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR\n   * Must agree to use contraception\u002Fbarrier and use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \\\u003C1% per year when having sexual intercourse with a woman of childbearing potential\n9. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be ≤ Grade 1 at the time of enrollment except for alopecia and Grade 2 peripheral neuropathy.\n10. Participants are able to comply with visit schedule and agree to weekly visits for 9 weeks\n\nExclusion Criteria:\n\n1. Systemic anti-myeloma therapy within ≤14 days or 5 half-lives, whichever is shorter, or plasmapheresis within 7 days prior to the first dose of study drug\n2. Systemic treatment with high dose steroids (equivalent to \\>60 mg prednisone daily for ≥4 days) within the past 14 days if administered to treat MM or non- MM disease\n3. Evidence of active bleeding\n4. Any major surgery within the last 28 days\n5. Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided participants fulfil entry criteria (as defined by inclusion criteria #6)\n6. Any serious and\u002For unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere participants' safety, obtaining informed consent or compliance with study procedures.\n7. Current unstable liver disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.\n8. Other malignancies are excluded, except for malignancy from which the patients have been disease-free for more than 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, prostate cancer or in situ cervical or breast cancer that has undergone potentially curative therapy.\n9. Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \\\u003C 50% of predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is \\\u003C 50% of predicted normal.\n10. Moderate or severe persistent asthma within the past 2 years (see Attachment XX), or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate.\n11. History of cardiovascular disease including any of the following:\n\n    1. History of clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including second degree (Mobitz Type II) or third degree atrioventricular (AV) block.\n    2. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of screening.\n    3. Class III or IV heart failure as defined by the New York Heart Association functional classification system.\n    4. Uncontrolled hypertension.\n12. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to daratumumab\n13. Active infection requiring treatment.\n14. Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb), at screening or within 3 months prior to first dose of study treatment. Note: presence of Hep B surface antibody positivity as the only serologic marker (HBsAb) indicating previous vaccination will not exclude a participant provided that patient has a known history of prior HBV vaccination Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing.\n15. Pregnant or lactating female",{"count":92,"type":21},30,[60,94],"PHASE2","The purpose of this study is to look at the safety, tolerability, and serum concentration of daratumumab administered subcutaneously in the thigh versus the abdomen in patients with plasma cell disorders. Daratumumab is a monoclonal antibody that can attach itself to the CD38 protein on the surface of abnormal plasma cells. Daratumumab can kill the abnormal plasma cells and\u002For help your immune system find and destroy them. Due to the way daratumumab works, normal cells may also be affected. All reference to the words \"study drug\" in this consent form will mean Daratumumab.\n\nDaratumumab has been approved by the U.S. Food and Drug Administration (FDA) alone or in combination with other standard of care drugs for treatment of multiple myeloma in both subcutaneous (DARZALEX FASPRO®) and intravenous (DARZALEX®) ways of being delivered. The FDA has also approved the subcutaneous administration of daratumumab combined with other standard of care drugs for patients with light chain (AL) amyloidosis. Subcutaneous means the drug is given by an injection just beneath the skin. Intravenous (IV) means the drug is given as an injection directly into a vein.\n\nUsually when given subcutaneously, the study drug is given by an injection in the abdomen. Having the drug given by subcutaneous injection (underneath the skin of the abdomen) has lessened the IV related side effects and the drug administration by injection is quicker.\n\nHowever, some patients cannot receive the study drug injections in their abdomen because they find them very painful or have other medical reasons making it difficult to get these injections. The goal of this study is to see if getting the study drug subcutaneously, injected under the skin by a needle, in the patient's upper thigh will have the same results, or better results, as getting the injection in the abdomen. This would therefore, improve patients access to the drug and provide an alternative place to receive the injection of the drug.\n\nThis study will take place at University of Maryland Medical Center and there will be about 30 people who will take place in this study here. Dr. Badros is the Sponsor-Investigator of the study. Funding to conduct the study and study drug are being provided by Johnson \\& Johnson Innovative Medicine (J\\&J IM).",[30],"2025-10-27",{"date":99,"type":39},"2025-10-29",{"date":101,"type":39},"2025-10-23",{"date":103,"type":21},"2032-10-01",{"name":105,"class":46},"University of Maryland, Baltimore",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":58,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100429974","phase-1-study-to-assess-safety-of-hdp-101-in-patients-with-relapsed-refractory-multiple-myeloma-100429974","NCT04879043","Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","A Phase 1\u002F2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma","Inclusion Criteria:\n\n* Male or female aged ≥18 years.\n* Life expectancy \\>12 weeks.\n* Eastern Cooperative Oncology Group Performance Status (PS) of 0 to 2.\n* A confirmed diagnosis of active MM according to the diagnostic criteria established by the International Myeloma Working Group (IMWG).\n* Must have undergone SCT or is considered transplant ineligible.\n* Must have undergone prior treatments with antimyeloma therapy which must have included an immunomodulatory drug, proteasome inhibitor, and anti-CD38 treatment, alone or in combination. In addition, the patient should either refractory or intolerant to any established standard of care therapy providing a meaningful clinical benefit for the patient assessed by the Investigator.\n* Measurable disease as per IMWG criteria.\n* Adequate organ system function as defined in protocol.\n\nExclusion Criteria:\n\n* For patient entering the Phase 2a part only: Prior treatment with any approved or experimental BCMA-targeting modalities are not allowed.\n* Known central nervous system involvement.\n* Plasma cell leukemia.\n* History of congestive heart failure.\n* Autologous or allogenic SCT within 12 weeks before the first infusion or is planning for autologous SCT.\n* Symptomatic graft versus host disease post allogenic hemopoietic cell transplant within 12 months prior to the first study treatment infusion.\n* Radiotherapy within 21 days prior to the first study treatment infusion.\n* History of any other malignancy known to be active.\n* Known human immunodeficiency virus infection.\n* Patients with active infection requiring systemic anti-infective.\n* Patients with positive test results for hepatitis B surface antigen or Hepatitis B core antigen.\n* Patients with positive test results for hepatitis C virus (HCV) infection.\n* Current active liver or biliary disease.",{"count":114,"type":21},78,[60,94],"This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.",[29,30],"2024-07-22",{"date":120,"type":39},"2024-07-24",{"date":122,"type":39},"2022-02-07",{"date":124,"type":21},"2026-05",{"name":126,"class":127},"Heidelberg Pharma AG","INDUSTRY",16,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100541517","disease-characteristics-and-treatment-response-in-plasma-cell-disorders-patients-based-on-genetic-abnormalities-from-fluorescence-in-situ-hybridization-and-next-generation-sequencing-100541517","NCT06330896","Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing","genetics MM","Inclusion Criteria:\n\n* Patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis\n* Aged 18 years and older\n* Performed FISH and\u002For NGS testing\n* Has treatment follow up at least one year\n\nExclusion Criteria:\n\n* Patients with missing crucial data that renders them unanalyzable\n* Patients who refuse to participate in the study",{"count":137,"type":21},498,"The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are:\n\n* genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and\u002For NGS testing\n* genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients.\n* disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and\u002For genetic mutations detected by NGS.\n* correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients.\n\nThe FISH and\u002For NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and\u002For NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.",[30],[30,141,142,143,144,145],"genetic abnormalities","Fluorescence In Situ Hybridization","FISH","Next Generation Sequencing","NGS","NOT_YET_RECRUITING","2024-03-19",{"date":149,"type":39},"2024-03-26",{"date":151,"type":21},"2024-04-01",{"date":153,"type":21},"2028-04-01",{"name":155,"class":46},"Siriraj Hospital"]